NVCR
HEALTHCARENovoCure Ltd
AI Insight
What's Moving NVCR Today?
No stock-specific AI insight has been generated for NVCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.82$20.55
$17.65
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.53
Dividend Yield—
Dividend / Share—
ROE-50.0%
Profit Margin-25.7%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding115.8M
NVCR News
26 articles- Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?Stocktwits·Jul 24, 2026
- Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval HopesYahoo Finance·Jul 24, 2026
- Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?'Yahoo Finance·Jul 23, 2026
- NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?Stocktwits·Jul 23, 2026
- NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...Yahoo Finance·Jul 23, 2026
- Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 OutlookAdvfn·Jul 23, 2026
- NovoCure Q2 Earnings Call HighlightsMarketbeat·Jul 23, 2026
- NovoCure (NVCR) Reports Q2 Loss, Beats Revenue EstimatesYahoo Finance·Jul 23, 2026
- NovoCure: Q2 Earnings Snapshotkare11.com·Jul 23, 2026
- Novocure Reports Second Quarter 2026 Financial ResultsYahoo Finance·Jul 23, 2026
- Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?Yahoo Finance·Jul 20, 2026
- NovoCure (NVCR) Could Be 39% Undervalued If Its Growth Narrative HoldsSimply Wall Street·Jul 19, 2026
- NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseYahoo Finance·Jul 16, 2026
- NovoCure's Cancer Treatment Device Option Pax Gets European ApprovalYahoo Finance·Jul 1, 2026
- Novocure to Report Second Quarter 2026 Financial ResultsYahoo Finance·Jul 1, 2026
- Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic CancerYahoo Finance·Jun 30, 2026
- NovoCure (NVCR) Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields StartSimply Wall Street·Jun 27, 2026
- HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?Motley Fool·Jun 24, 2026
- NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?Motley Fool·Jun 22, 2026
- NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial MissYahoo Finance·Jun 20, 2026
- Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?Motley Fool·Jun 19, 2026
- Stocks Sharply Higher as US-Iran Peace Deal Eases Inflation RisksBarchart·Jun 18, 2026
- Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain CancerYahoo Finance·Jun 18, 2026
- [144] NovoCure Ltd SEC FilingStock Titan·Jun 5, 2026
- NovoCure Ltd stock (JE00B6T5S470): Up 40% YTD on oncology innovationAD HOC NEWS·May 14, 2026
- [SCHEDULE 13G/A] NovoCure Ltd Amended Passive Investment DisclosureStock Titan·May 9, 2026
All 26 articles loaded
Price Data
Open$20.68
Previous Close$19.99
Day High$21.45
Day Low$17.60
52 Week High$20.55
52 Week Low$9.82
52-Week Range
$9.82$20.55
$17.65
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-1.53
Dividend Yield—
Dividend / Share—
ROE-50.0%
Profit Margin-25.7%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding115.8M
About NovoCure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—